BRCA1 antibody | MS13

100% Secure


Mouse anti Human BRCA1 (N-Terminal)

Product Type
Monoclonal Antibody
Clone
MS13
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
MCA1683GT IF IP P WB 50 µg
Mouse anti Human BRCA1 antibody, clone MS13 recognizes the human tumor suppressor protein BRCA-1, also known as Breast cancer type 1 susceptibility protein or RING finger protein 53. BRCA1 is a 1863 amino acid, ~220kDa E3 ubiquitin-protein ligase playing a central role in DNA repair (Tibbetts et al. 2000), expressed in the nucleus during the S/G2 phase of the cell cycle (Durrant and Nickoloff 2005). Normal BRCA-1 acts as a tumor suppressor protein and mutation or dysregulation of BRCA1 may indicate high risk of development of disease, including breast cancer (Budhram-Mahadeo et al. 1999). Mouse anti human BRCA-1, clone MS13 recognizes an epitope within the 304 amino acid N-Terminal (NT) region (Yoshikawa et al. 1999) of human BRCA1.

BRCA1 is expressed numerous organs including mammary and ovarian tissues (Miki et al. 1994) . Mutations in the BRCA-1 gene are associated with hereditary breast and ovarian cancers, particularly at a younger age of diagnosis. Women carrying BRCA1 mutations have a 50-95% chance of developing breast cancer in later life (Elit 2001), secondary cancers such as prostate or melanoma also frequently arise in the latter stages of both male and female breast cancer patients (Benevento et al. 2012), but genetic screening and increased awareness of preventative surgery, can reduce this risk significantly (Scheuer et al. 2002). However, in males pancreatic and prostate cancer appear to be more strongly associated with BRCA2 gene mutations (Gallagher et al. 2010).

BRCA1 is a key marker of triple-negative breast cancer (TNBC), a high risk aggressive cancer which makes up about 15% of invasive breast cancers, and lacks the benefit of specific targeted therapy (Duffy et al. 2012). Triple-negative tumors are predominantly basal-like, poorly differentiated and of higher histological grade. Younger women have an increased rate of basal or BRCA related TNBC, compared with the higher proportion of apocrine, normal-like and rare subtypes of TNBC, seen in older women (Liu et al. 2009).

Studies looking at sporadic breast cancer, have shown that clone MS13 strongly correlates with poor patient prognosis, and appears to label the Δ11b splice variant of BRCA1, suggesting that Δ11b could act as a negative marker in the prognosis of sporadic breast cancer (Fraser et al. 2003).

Mouse anti human BRCA1 antibody, clone MS13 is suitable for use in the immunohistochemical staining of human breast (Fraser et al. 2003) and for immunofluorescence in multiple cell lines (Scully et al. 1996).

Product Details

Target Species
Human
Product Form
Purified IgG - liquid
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution
TRIS-glycine buffered saline, NaCl
Preservative Stabilisers
0.05% Sodium Azide
Immunogen
Recombinant protein corresponing to the N-Terminal region of human BRCA1
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml
Fusion Partners
Spleen cells from immunised mice were fused with cells of the mouse NS1 myeloma cell line.

Storage Information

Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
18 months from date of despatch

More Information

UniProt
P38398 Related reagents
Entrez Gene
BRCA1 Related reagents
GO Terms
GO:0007059 chromosome segregation
GO:0005515 protein binding
GO:0000724 double-strand break repair via homologous recombination
GO:0003677 DNA binding
GO:0003713 transcription coactivator activity
GO:0003723 RNA binding
GO:0030529 ribonucleoprotein complex
GO:0006915 apoptosis
GO:0004842 ubiquitin-protein ligase activity
GO:0005654 nucleoplasm
GO:0006301 postreplication repair
GO:0006359 regulation of transcription from RNA polymerase III promoter
GO:0006633 fatty acid biosynthetic process
GO:0006978 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator
GO:0007049 cell cycle
GO:0008270 zinc ion binding
GO:0008274 gamma-tubulin ring complex
GO:0008630 DNA damage response, signal transduction resulting in induction of apoptosis
GO:0042802 identical protein binding
GO:0010212 response to ionizing radiation
GO:0010552 positive regulation of gene-specific transcription from RNA polymerase II promoter
GO:0015631 tubulin binding
GO:0016481 negative regulation of transcription
GO:0016563 transcription activator activity
GO:0030521 androgen receptor signaling pathway
GO:0031398 positive regulation of protein ubiquitination
GO:0031436 BRCA1-BARD1 complex
GO:0031572 G2/M transition DNA damage checkpoint
GO:0031625 ubiquitin protein ligase binding
GO:0042127 regulation of cell proliferation
GO:0043627 response to estrogen stimulus
GO:0045717 negative regulation of fatty acid biosynthetic process
GO:0045739 positive regulation of DNA repair
GO:0046600 negative regulation of centriole replication
GO:0050681 androgen receptor binding
GO:0051865 protein autoubiquitination
GO:0070531 BRCA1-A complex
GO:0071681 cellular response to indole-3-methanol
GO:0085020 protein K6-linked ubiquitination
Regulatory
For research purposes only

Applications of BRCA1 antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Immunofluorescence 1/500
Immunohistology - Paraffin 1/50
Immunoprecipitation
Western Blotting 0.5ug/ml
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Histology Positive Control Tissue
Breast carcinoma
Western Blotting
Mouse anti Human BRCA1 detects a band of approximately 220kDa in HeLa nuclear extract. Some cell lysates may also show an uncharacterized band of approximately 65kDa.

Secondary Antibodies Available

Description Product Code Pack Size Applications List Price Quantity
Human anti Mouse IgG1:HRP HCA036P 0.1 mg E
Goat anti Mouse IgG (H/L):Alk. Phos. (Multi Species Adsorbed) STAR117A 0.5 mg E WB
Goat anti Mouse IgG (H/L):DyLight®488 (Multi Species Adsorbed) STAR117D488GA 0.1 mg F IF
Goat anti Mouse IgG (H/L):DyLight®549 (Multi Species Adsorbed) STAR117D549GA 0.1 mg F IF WB
Goat anti Mouse IgG (H/L):DyLight®649 (Multi Species Adsorbed) STAR117D649GA 0.1 mg F IF
Goat anti Mouse IgG (H/L):DyLight®680 (Multi Species Adsorbed) STAR117D680GA 0.1 mg F WB
Goat anti Mouse IgG (H/L):DyLight®800 (Multi Species Adsorbed) STAR117D800GA 0.1 mg F IF WB
Goat anti Mouse IgG (H/L):FITC (Multi Species Adsorbed) STAR117F 0.5 mg F
Goat anti Mouse IgG (H/L):HRP (Multi Species Adsorbed) STAR117P 0.5 mg E WB
Goat anti Mouse IgG (Fc):FITC STAR120F 1 mg C F
Goat anti Mouse IgG (Fc):HRP STAR120P 1 mg E WB
Rabbit F(ab')2 anti Mouse IgG:RPE STAR12A 1 ml F
Rabbit F(ab')2 anti Mouse IgG:HRP (Human Adsorbed) STAR13B 1 mg C E P RE WB
Goat anti Mouse IgG:FITC (Rat Adsorbed) STAR70 0.5 mg F
Goat anti Mouse IgG:RPE (Rat Adsorbed) STAR76 1 ml F
Goat anti Mouse IgG:HRP (Rat Adsorbed) STAR77 0.5 mg C E P
Goat anti Mouse IgG/A/M:Alk. Phos. STAR87A 1 mg C E WB
Goat anti Mouse IgG/A/M:HRP (Human Adsorbed) STAR87P 1 mg E
Rabbit F(ab')2 anti Mouse IgG:Dylight®800 STAR8D800GA 0.1 mg F IF WB
Rabbit F(ab')2 anti Mouse IgG:FITC STAR9B 1 mg F

Product Specific References

References for BRCA1 antibody

  1. Scully, R. et al. (1996) Location of BRCA1 in human breast and ovarian cancer cells.
    Science. 272 (5258): 123-6.
  2. Yoshikawa, K. et al. (1999) Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.
    Clin Cancer Res. 5 (6): 1249-61.
  3. Ribeiro-Silva, A. et al. (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer.
    Histopathology. 47: 458-66
  4. Oliveira-Costa, J.P. et al. (2010) Significance of topoisomerase IIIβ expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis.
    Hum Pathol. 41: 1624-30.
  5. Oliveira-Costa, J.P. et al. (2014) BRCA1 and γH2AX as independent prognostic markers in oral squamous cell carcinoma.
    Oncoscience. 1 (5): 383-91.
  6. Ribeiro-Silva, A. et al. (2006) Expression of checkpoint kinase 2 in breast carcinomas: correlation with key regulators of tumor cell proliferation, angiogenesis, and survival.
    Histol Histopathol. 21 (4): 373-82.
  7. Meng, Z.H. et al. (2004) Aberrations of breast cancer susceptibility genes occur early in sporadic breast tumors and in acquisition of breast epithelial immortalization.
    Genes Chromosomes Cancer. 41 (3): 214-22.

Further Reading

  1. Fraser, J.A. et al. (2003) A role for BRCA1 in sporadic breast cancer.
    Br J Cancer. 88: 1263-70.